1. Kushiyama A, Nakatsu Y, Matsunaga Y, Yamamotoya T, Mori K, Ueda K, et al. 2016; Role of uric acid metabolism-related inflammation in the pathogenesis of metabolic syndrome components such as atherosclerosis and nonalcoholic steatohepatitis. Mediators Inflamm. 2016:8603164. DOI:
10.1155/2016/8603164. PMID:
28070145. PMCID:
PMC5192336.
Article
3. Gherghina ME, Peride I, Tiglis M, Neagu TP, Niculae A, Checherita IA. 2022; Uric acid and oxidative stress-relationship with cardiovascular, metabolic, and renal impairment. Int J Mol Sci. 23:3188. DOI:
10.3390/ijms23063188. PMID:
35328614. PMCID:
PMC8949471.
Article
4. Yu MA, Sánchez-Lozada LG, Johnson RJ, Kang DH. 2010; Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens. 28:1234–42. DOI:
10.1097/HJH.0b013e328337da1d.
Article
5. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. 2007; Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol. 293:C584–96. Erratum in: Am J Physiol Cell Physiol 2010;299:C726. DOI:
10.1152/ajpcell.00600.2006. PMID:
17428837.
Article
6. Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, et al. 2018; Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the National Kidney Foundation. Am J Kidney Dis. 71:851–65. DOI:
10.1053/j.ajkd.2017.12.009. PMID:
29496260. PMCID:
PMC7286363.
Article
7. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. 2000; Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension. 36:1072–8. DOI:
10.1161/01.HYP.36.6.1072. PMID:
11116127.
Article
8. Deng Y, Liu F, Yang X, Xia Y. 2021; The key role of uric acid in oxidative stress, inflammation, fibrosis, apoptosis, and immunity in the pathogenesis of atrial fibrillation. Front Cardiovasc Med. 8:641136. DOI:
10.3389/fcvm.2021.641136. PMID:
33718459. PMCID:
PMC7952317.
Article
9. Yamada S, Suzuki H, Kamioka M, Kamiyama Y, Saitoh S, Takeishi Y. 2012; Uric acid increases the incidence of ventricular arrhythmia in patients with left ventricular hypertrophy. Fukushima J Med Sci. 58:101–6. DOI:
10.5387/fms.58.101. PMID:
23237865.
Article
10. Lee TM, Lin SZ, Chang NC. 2016; Effects of urate-lowering agents on arrhythmia vulnerability in post-infarcted rat hearts. J Pharmacol Sci. 131:28–36. DOI:
10.1016/j.jphs.2016.03.009. PMID:
27129614.
Article
12. Tabayashi K, Suzuki Y, Nagamine S, Ito Y, Sekino Y, Mohri H. 1991; A clinical trial of allopurinol (Zyloric) for myocardial protection. J Thorac Cardiovasc Surg. 101:713–8. DOI:
10.1016/S0022-5223(19)36703-0. PMID:
2008110.
Article
13. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. 2000. Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute;Ottawa:
14. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. 2019; RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 366:l4898. DOI:
10.1136/bmj.l4898. PMID:
31462531.
Article
16. Kojima S, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Hiramitsu S, et al. 2022; Optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks: post hoc analysis of a randomized controlled trial. Rheumatology (Oxford). 61:2346–59. DOI:
10.1093/rheumatology/keab739. PMID:
34605897.
18. Tai CJ, Wu CC, Lee KT, Tseng TG, Wang HC, Chang FR, et al. 2022; The impact of urate-lowering therapy in post-myocardial infarction patients: insights from a population-based, propensity score-matched analysis. Clin Pharmacol Ther. 111:655–63. DOI:
10.1002/cpt.2473. PMID:
34719019. PMCID:
PMC9298734.
Article
19. Gao Z, Shi H, Xu W, Guan Z, Su X, Guo N, et al. 2022; Hyperuricemia increases the risk of atrial fibrillation: a systematic review and meta-analysis. Int J Endocrinol. 2022:8172639. DOI:
10.1155/2022/8172639. PMID:
36046801. PMCID:
PMC9420608.
Article
20. Anzai N, Ichida K, Jutabha P, Kimura T, Babu E, Jin CJ, et al. 2008; Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem. 283:26834–8. Erratum in: J Biol Chem 2008;283:32152. DOI:
10.1016/S0021-9258(20)56959-7.
Article
21. Mandurino-Mirizzi A, Crimi G, Raineri C, Pica S, Ruffinazzi M, Gianni U, et al. 2018; Elevated serum uric acid affects myocardial reperfusion and infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. J Cardiovasc Med (Hagerstown). 19:240–6. DOI:
10.2459/JCM.0000000000000634. PMID:
29470249.
Article
22. Liang X, Zhang Q, Wang X, Yuan M, Zhang Y, Xu Z, et al. 2018; Reactive oxygen species mediated oxidative stress links diabetes and atrial fibrillation. Mol Med Rep. 17:4933–40. DOI:
10.3892/mmr.2018.8472. PMID:
29393403. PMCID:
PMC5865952.
Article
23. D'Oria R, Schipani R, Leonardini A, Natalicchio A, Perrini S, Cignarelli A, et al. 2020; The role of oxidative stress in cardiac disease: from physiological response to injury factor. Oxid Med Cell Longev. 2020:5732956. DOI:
10.1155/2020/5732956. PMID:
32509147. PMCID:
PMC7244977.
24. Xu D, Murakoshi N, Tajiri K, Duo F, Okabe Y, Murakata Y, et al. 2021; Xanthine oxidase inhibitor febuxostat reduces atrial fibrillation susceptibility by inhibition of oxidized CaMKII in Dahl salt-sensitive rats. Clin Sci (Lond). 135:2409–22. DOI:
10.1042/CS20210405. PMID:
34386810.
Article
25. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. 2010; Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 375:2161–7. DOI:
10.1016/S0140-6736(10)60391-1. PMID:
20542554.
Article
26. Beattie CJ, Fulton RL, Higgins P, Padmanabhan S, McCallum L, Walters MR, et al. 2014; Allopurinol initiation and change in blood pressure in older adults with hypertension. Hypertension. 64:1102–7. DOI:
10.1161/HYPERTENSIONAHA.114.03953. PMID:
25135183.
Article
27. Rekhraj S, Gandy SJ, Szwejkowski BR, Nadir MA, Noman A, Houston JG, et al. 2013; High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol. 61:926–32. DOI:
10.1016/j.jacc.2012.09.066. PMID:
23449426.
Article
28. Sakabe M, Fujiki A, Sakamoto T, Nakatani Y, Mizumaki K, Inoue H. 2012; Xanthine oxidase inhibition prevents atrial fibrillation in a canine model of atrial pacing-induced left ventricular dysfunction. J Cardiovasc Electrophysiol. 23:1130–5. DOI:
10.1111/j.1540-8167.2012.02356.x. PMID:
22587612.
Article
29. Chou HW, Chiu HT, Tsai CW, Ting IW, Yeh HC, Huang HC, et al. 2018; Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. Nephrol Dial Transplant. 33:1620–7. DOI:
10.1093/ndt/gfx313. PMID:
29165620. PMCID:
PMC5837776.
Article